/PRNewswire/ ABILITY DIABETES-GLOBAL (ADG), is the World s largest Randomized Controlled Trial (RCT) for patients with DM (Diabetes Mellitus), comparing.
Get latest articles and stories on Business at LatestLY. ABILITY DIABETES-GLOBAL (ADG), is the World s largest Randomized Controlled Trial (RCT) for patients with DM (Diabetes Mellitus), comparing head-to-head the Sirolimus eluting stent, Abluminus DES+ (Concept Medical Inc.) with the XIENCE family of DES (Abbott Cardiovascular). Business News | ABILITY DIABETES GLOBAL - A Landmark RCT in the Field of PCI for Patients with DM, Completes Enrolment.